Numerate in the News

Numerate, my company, has been getting some press lately.

• Our CEO wrote an article about our business model which is in Nature Biotechnology. It is a good read even though the editor transformed it a lot from the original.
• A blogger over at PEHub heard about us and wrote an article about who we are and what we are trying to do. She interviewed one of our lead investors Adam Grosser, from Foundation Capital, and our CEO Guido Lanza.
  

Also, our CTO, Nigel Duffy, and CSO, John Griffin, will also be presenting talks at the upcoming ACS fall 2009 meeting.

• Machine learning and drug discovery: Never the twain shall meet?
• Drug engineering of dual-acting HMG-CoA reductase + p38α MAP kinase inhibitors